SLXN fundamentals
An in-depth look to Silexion Therapeutics Corp operating, investing, and financing activities
SLXN free cash flow for Q2 24 is -103.34 k USD. For 2023, SLXN free cash flow was 306.38 k USD and operating cash flow was 306.38 k USD.
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
TTM